Manufacturer
AbbVie Ltd(UNITED STATES)
Registraction Number
MAL19106011ACRZ
Contents:
• Active Ingredient: Olaparib 100 mg per tablet
• Inactive Ingredients: Copovidone, Colloidal anhydrous silica, Mannitol, Sodium stearyl fumarate (tablet core); Hypromellose, Macrogol 400, Titanium dioxide (E171), Iron oxide yellow (E172), Iron oxide black (E172) (150 mg tablets only)
Indications:
Lynparza is used for the treatment of various cancers, including:
• Ovarian Cancer: Maintenance treatment for advanced BRCA1/2-mutated high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• Breast Cancer: Adjuvant treatment for HER2-negative, high-risk early breast cancer, and treatment for metastatic breast cancer with BRCA1/2 mutations.
• Pancreatic Cancer: Maintenance treatment for metastatic adenocarcinoma of the pancreas with BRCA1/2 mutations.
• Prostate Cancer: Treatment for metastatic castration-resistant prostate cancer with BRCA1/2 mutations.
Instructions:
• Dosage: The recommended dose is 300 mg orally twice daily with or without food. For moderate renal impairment, the dose is reduced to 200 mg twice daily3.
• Administration: Take the tablets exactly as prescribed by your healthcare provider.
• Monitoring: Regular monitoring by a physician experienced in the use of anticancer therapies is necessary.
• Precautions: Do not substitute Lynparza tablets with capsules due to differences in dosing and bioavailability.
Malaysia
